A retrospective study of patients with chronic myeloid leukemia diagnosed and treated at the Chaim Sheba Medical Center during the years 1966-76.
Forty patients with chronic myeloid leukemia diagnosed and treated at the Chaim Sheba Medical Center, Tel-Hashomer, during the period 1966-76 were reviewed. All the patients were treated initially with busulfan (MYLERAN). Asymptomatic patients or those whose blood counts were stable and remained below 50,000/microliter were not treated. Maintenance therapy was not prescribed as a routine. The median survival time of all the patients was over 60 months--longer than reported in the literature. Prognostic parameters for longer survival were found to be Hb level greater than 10 g/dl at the time of diagnosis (P = 0.04) and duration of first remission in the chronic stage more than six months (P = 0.03). A borderline trend for better survival was found in patients with initial platelet counts above 100,000/microliter (P = 0.07).
D002066:Busulfan / Q000009:adverse effects / Q000627:therapeutic use; D006801:Humans; D006918:Hydroxyurea / Q000009:adverse effects; D007951:Leukemia, Myeloid / Q000175:diagnosis* / Q000188:drug therapy; D011379:Prognosis; D012189:Retrospective Studies
D002066:Busulfan; D006918:Hydroxyurea